-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $9

Benzinga·12/10/2025 12:33:00
Listen to the news
B. Riley Securities analyst Mayank Mamtani initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $9.